Rad Habib Sadeghi, Shiravand Yavar, Radfar Payar, Ladwa Rahul, Perry Chris, Han Xiaoyuan, Warkiani Majid Ebrahimi, Adams Mark N, Hughes Brett Gm, O'Byrne Ken, Kulasinghe Arutha
University of Queensland Diamantina Institute the University of Queensland Brisbane QLD Australia.
Department of Molecular Medicine and Medical Biotechnology University of Naples Federico II Naples Italy.
Clin Transl Immunology. 2022 Jun 6;11(6):e1397. doi: 10.1002/cti2.1397. eCollection 2022.
Head and neck squamous cell carcinoma (HNSCC) represents a heterogeneous group of tumors. While significant progress has been made using multimodal treatment, the 5-year survival remains at 50%. Developing effective therapies, such as immunotherapy, will likely lead to better treatment of primary and metastatic disease. However, not all HNSCC tumors respond to immune checkpoint blockade therapy. Understanding the complex cellular composition and interactions of the tumor microenvironment is likely to lead to new knowledge for effective therapies and treatment resistance. In this review, we discuss HNSCC characteristics, predictive biomarkers, factors influencing immunotherapy response, with a focus on the tumor microenvironment.
头颈部鳞状细胞癌（HNSCC）是一组异质性肿瘤。虽然多模式治疗已取得显著进展，但5年生存率仍维持在50%。开发有效的治疗方法，如免疫疗法，可能会改善原发性和转移性疾病的治疗效果。然而，并非所有HNSCC肿瘤都对免疫检查点阻断疗法有反应。了解肿瘤微环境复杂的细胞组成和相互作用，可能会为有效治疗和治疗耐药性带来新知识。在本综述中，我们将讨论HNSCC的特征、预测性生物标志物、影响免疫治疗反应的因素，重点关注肿瘤微环境。
